- Company
- Zerbaxa's benefit in 5 Years
- by Oct 28, 2022 05:57am
- After five years of domestic approval, the MSD super antibiotic "Zerbaxa (Ceftolozane/Tazobactam)" was registered. It is expected to help reduce the recent surge in carbapenem antibiotic resistance. MSD Korea held a press conference at the Koreana Hotel in Jung-gu, Seoul on the 27th to commemorate the registration of Zerbaxa, a multidrug-resi
- Company
- AZ-Abbott to copromote diabetic kidney disease treatments
- by Eo, Yun-Ho Oct 28, 2022 05:56am
- On the 26th, AstraZeneca Korea announced that it had signed a joint promotion agreement with Abbott Korea for the early diagnosis and treatment of patients with diabetic kidney disease. The signing ceremony was held at AstraZeneca Korea’s headquarters in Samseong-dong, Seoul on the 25th ,in the presence of key officials from both compani
- Company
- Vaccine Development in 100 Days of Pandemic
- by Oct 28, 2022 05:55am
- Vaccine and bio leaders around the world have set a goal of "100 days of vaccine development" as a countermeasure to the "Next Pandemic." To achieve this, it requested organic cooperation from governments, industries, international organizations, and academia. It also predicted that Korea will play an important role in resolving the deepening in
- Company
- Influenza epidemic and the launch of generic products
- by Kim, Jin-Gu Oct 28, 2022 05:55am
- The Peramiflu-based flu treatment market, which was monopolized by GC Pharma, will be reorganized into a system in which 15 companies compete during the flu season this winter. In particular, unlike the past two years, when the number of flu patients plunged due to the prolonged COVID-19, the competition in this market is expected to be very
- Company
- The New Testament Era of Rosuzet and K-CAB
- by Chon, Seung-Hyun Oct 28, 2022 05:55am
- Domestic developed drugs continued to be strong in the foreign prescription drug market. Hanmi Pharmaceutical's complex new drug Rosuzet exceeded 100 billion won in prescriptions in three quarters, while HK inno.N's new drug K-CAB booked 100 billion won for the second consecutive year. According to UBIST, a drug research institute, on the 23r
- Company
- Dexeryl for atopic dermatitis lands in Korea
- by Oct 27, 2022 05:52am
- Pierre Fabre Korea announced that it had launched its medical device cream ‘Dexeryl’ in Korea on the 26th. Dexeryl is an MD cream that represents the 60-year-old French pharmaceutical company, Pierre Fabre. It is used to treat dryness of the skin and symptoms from skin conditions, such as atopic dermatitis, pruritus, diabetic foot dise
- Company
- The unfinished aftershocks of COVID-19
- by Chon, Seung-Hyun Oct 26, 2022 05:50am
- The market for outpatient prescription drugs was the largest ever. This year, the prescription market has grown significantly due to the expansion of prescriptions such as cold medicine due to the rapid increase in the number of COVID-19 confirmed patients. The size of Expectant prescriptions used to relieve COVID-19 symptoms has more than doubl
- Company
- First TYK2 inhibitor Sotyktu will enter Korean market
- by Eo, Yun-Ho Oct 26, 2022 05:50am
- The oral TYK2 inhibitor for psoriasis will soon be introduced to Korea. According to industry sources, BMS Korea applied for domestic marketing authorization for its tyrosine kinase 2 (TYK2) inhibitor ‘Sotyktu (deucravacitinib) in Korea. The drug was approved for the treatment of adults with moderate-to-severe plaque psoriasis who are
- Company
- Xarelto sales fall 30% due to generics and price cuts
- by Oct 26, 2022 05:50am
- The quarterly prescription of new oral anticoagulants (NOAC) containing rivaroxaban, which had reached KRW 15 billion, has shrunk to KRW 13 billion. This decrease is interpreted to be reflected by the price cut of Bayer’s original ‘Xarelto.’ Its generics that entered the market 1 year ago have been starting to slowly increase their share in t
- Company
- Genuone challenges Trajenta’s non-listed patent...Why?
- by Kim, Jin-Gu Oct 25, 2022 05:46am
- Genuone Sciences has challenged the unlisted patents of Trajenta (linagliptin). Industry interpretations are that the move is the company’s strategy to remove uncertainties in releasing generic versions of Trajenta and to additionally attract CMO deals” According to industry sources on the 24th, Genuone Sciences filed a trial to co
